Melanotan II side effects: the mole problem, priapism and serious rare events

Most “research peptides” have a thin safety file because almost nobody has studied them in people. Melanotan II is the opposite case: it has been injected widely enough, for long enough, that a genuine harm record exists in the medical literature — and that record is the reason this page is written as a warning rather than a how-to. For the pharmacology and the broader regulatory picture, see the melanotan II evidence monograph; this page is the dedicated look at what actually goes wrong.

The common effects: nausea, flushing and yawning

Even in a controlled clinical setting, MT-2 is not a comfortable drug. In a human study pairing a superpotent melanotropic peptide with solar ultraviolet exposure, the investigators recorded nausea and facial flushing among participants — effects that track directly to the drug rather than the sun.^[1] Yawning, transient queasiness and a flushed, warm sensation in the minutes after a dose are the most frequently reported low-grade complaints, and a peer-reviewed review of unregulated α-melanocyte-stimulating hormone analogue use lists this constellation as the routine background of MT-2 exposure.^[2] These are rarely dangerous on their own. They matter because they are constant reminders that the molecule is reaching melanocortin receptors well beyond the skin.

The mole problem — the side effect that matters most

For a drug whose mechanism is to amplify melanocyte activity, the most consequential adverse effect is what it does to moles, and here the literature is unusually concrete. A report in the BMJdocumented a person whose moles visibly changed after using an unlicensed “sun tan jab,” raising the alarm that pigment-driving injections can alter the very lesions clinicians watch.^[3] A separate dermatology case described eruptive new naevi and darkening of pre-existing moles within 24 hours of a single MT-2 injection — a startlingly rapid melanocytic response.^[4]

The clinical danger is twofold. First, MT-2 can darken and enlarge existing moles, which confounds the visual surveillance — change in colour, size and border — that dermatologists rely on to catch melanoma early. Second, it generates entirely new pigmented lesions whose long-term behaviour nobody has characterised. The review of α-MSH analogue risks treats these melanocytic changes as a central reason for caution rather than a footnote.^[2] The practical upshot is blunt: anyone who has used MT-2 should have a clinician review their moles, and any changing lesion deserves urgent assessment.

Priapism: a urological emergency

Because MT-2 activates central melanocortin pathways that influence erectile function, one of its best-documented acute harms is priapism — a prolonged, painful erection that is a medical emergency and can cause permanent damage if not treated promptly. A toxicology report linked priapism directly to MT-2 overdose,^[5] and a separate case in BMJ Case Reportsdescribed melanotan-induced priapism requiring intervention — memorably titled “a hard-earned tan.”^[6] Because the powder is dosed by guesswork rather than a label, the line between “tanning dose” and a dose that triggers priapism is exactly the kind of margin an unregulated product cannot guarantee.

Blood pressure, renal infarction and PRES

MT-2’s reach into the cardiovascular system turns its blood-pressure effects from a nuisance into a rare-but-real danger. A published case implicated MT-2 in a renal infarction — a clot-driven loss of blood supply to part of a kidney — underlining that its vascular effects are not merely theoretical.^[7] More striking still, MT-2 has been associated with posterior reversible encephalopathy syndrome (PRES), a serious neurological condition of headache, visual disturbance and seizures that is closely tied to acute surges in blood pressure.^[8] Each of these is individually rare. Together they describe a molecule with genuine systemic reach — which is exactly what an agonist hitting receptors throughout the body, at uncontrolled self-injected doses, would be expected to produce.

It is the supply, too: an uncontrolled dose of an unverified product

Every harm above is compounded by a second, independent problem: MT-2 has no legitimate pharmacy route, so what is sold is gray-market powder of unverified content, reconstituted and dosed by the user. There is no approved concentration and no dosing label — which is why this site does not publish an injection protocol for it and why our melanotan II dosage page is framed around why a safe number cannot be given. An unknown quantity of an unknown-purity peptide makes every one of these side-effect risks harder to predict, not easier. The sourcing problem itself is covered in where to get peptides safely.

The regulators have already said this

None of this is a fringe interpretation. The U.S. Food and Drug Administration has acted against unapproved “tanning” products containing melanotan, and the UK’s Medicines and Healthcare products Regulatory Agency has issued repeated public warnings that Melanotan II is unlicensed, of unknown safety, and should not be used. Their consumer guidance is direct: do not buy or use it. These positions sit alongside the clinical literature, not in tension with it — both point the same way.

The honest bottom line

Melanotan II’s side-effect profile is the strongest argument against using it. The common effects — nausea, flushing, yawning — are merely unpleasant.^[1] The dermatologic signal is the one that should stop people: it darkens existing moles and seeds new ones, undermining the exact surveillance that catches melanoma early.^[3][4] And the tail of the distribution holds genuinely dangerous events — priapism, renal infarction, PRES.^[5][7][8] All of it is delivered by an unapproved powder at a dose nobody can verify, against the explicit warnings of two major regulators. If you have used it, the single most useful step is a dermatology mole check. To weigh better-supported options, browse our peptide evidence matrix.